Rx Statin Market Growth Could Be Result Of Low-Dose Switch – J&J’s Perkins
This article was originally published in The Tan Sheet
Executive Summary
An OTC statin switch will lead to growth in the Rx market rather than cannibalization, Johnson & Johnson Worldwide Chairman for Consumer Pharmaceuticals & Nutritionals Brian Perkins predicted